<DOC>
	<DOC>NCT00002433</DOC>
	<brief_summary>To determine safety and tolerance of administering aerosolized recombinant interferon gamma (IFN-gamma) for 4 weeks in patients with AIDS. To examine activation of alveolar macrophages by aerosolized IFN-gamma administration. To determine if subcutaneous (SC) injection of IFN-gamma can activate alveolar macrophages in AIDS patients.</brief_summary>
	<brief_title>The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>Inclusion Criteria Patients must have: Diagnosis of AIDS with one or more opportunistic infections. Kaposi's sarcoma with prior history of opportunistic infection. Stable dose of zidovudine (AZT) therapy. Preserved pulmonary, renal and hepatic function. Exclusion Criteria Coexisting Condition: Patients with the following conditions or symptoms are excluded: Presence of active infection. Active opportunistic infections. Cardiac disease. Central nervous system disorders. History of seizures. Irreversible airway disease. Patients with the following are excluded: Coexisting conditions and symptoms listed in Patient Exclusion Coexisting Conditions. Prior Medication: Excluded within 4 weeks of study entry: Immunosuppressive therapy. Cytotoxic therapy. Excluded: Interferon gamma therapy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 1999</verification_date>
	<keyword>Pulmonary Alveoli</keyword>
	<keyword>Macrophage Activation</keyword>
	<keyword>Interferon-gamma, Recombinant</keyword>
	<keyword>Injections, Subcutaneous</keyword>
	<keyword>Aerosols</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>